BAROSTIM NEO System in the Treatment of Heart Failure
Neo Randomized Heart Failure Study
Sponsor: CVRx, Inc.
This NA trial investigates Heart Failure and is currently ongoing. CVRx, Inc. leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Nov 2021 — Jul 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Nov 2021 [monthly]
Active Not Recruiting NA
▶ Show 5 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Completed → Active Not Recruiting
-
Jun 2018 — Dec 2019 [monthly]
Completed NA
-
Mar 2018 — Jun 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CVRx, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ancona, Italy , Bergamo, Italy , Berlin, Germany , Bernau, Germany , Calgary, Canada , Cologne, Germany , Edmonton, Canada , Essen, Germany , Florence, Italy , Frankfurt, Germany and 19 more locations